BioPharma Resources

Drug Trial Radar · NCT07277231

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jan 22, 2026

Primary completion

Feb 2031

Study completion Nov 2031

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Dec 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • SonrotoclaxDrug

    Administered orally.

  • ZanubrutinibDrug

    Administered orally.

  • AcalabrutinibDrug

    Administered orally.

  • VenetoclaxDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)Time frame: Up to approximately 70 months
  2. Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)Time frame: Up to approximately 16 months

Locations

115 sites in 17 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • Rocky Mountain Cancer Centers (Williams) Usor

    Aurora, Colorado · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Mount Sinai Medical Center Braman Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Midwestern Regional Medical Center

    Zion, Illinois · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Atrium Health Levine Cancer Institute (Lci)

    Charlotte, North Carolina · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Oncology Associates of Oregon Willamette Valley Cancer Center

    Eugene, Oregon · Recruiting

  • Upmc Hillman Cancer Center(Univ of Pittsburgh)

    Pittsburgh, Pennsylvania · Recruiting

  • Texas Oncology Tyler

    Tyler, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • Genesiscare North Shore

    St Leonards, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Cabrini Hospital Malvern

    Malvern, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Instituto Dor de Pesquisa E Ensino Distrito Federal

    Brasília, Brazil · Recruiting

  • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus

    Porto Alegre, Brazil · Recruiting

  • Ensino E Terapia de Inovacao Clinica Amo Etica

    Salvador, Brazil · Recruiting

  • Instituto Dor de Pesquisa E Ensino Sao Paulo

    São Paulo, Brazil · Recruiting

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    São Paulo, Brazil · Recruiting

  • Bc Cancer Victoria

    Victoria, British Columbia, Canada · Recruiting

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada · Recruiting

  • Ciusss Nim Hscm

    Montreal, Quebec, Canada · Recruiting

  • Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

  • Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)

    Québec, Quebec, Canada · Recruiting

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.